CAR T-cell Therapy Market Forecast, Top Companies, Size, Share and Trend by 2031Posted by Shrikant Mandlik on September 12th, 2022 CAR T-cell Therapy Market: Introduction According to the report, the global CAR T-cell therapy market was valued at US$ 1.1 Bn in 2020 and is projected to expand at a CAGR of 30.6% from 2021 to 2031. CAR T-cell therapy is a recently approved treatment option for various types of cancer. CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient. Currently, Kymriah, Yescarta, Tecartus, Breyanzi, and ABECMA are the CAR T-cell therapy approved products for acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. Request a Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83242 The global CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline. North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early adoption of new products, high prevalence rate of cancer, and presence of major players are expected to propel the CAR T-cell therapy market in North America. Asia Pacific is likely to be a highly lucrative market for CAR T-cell therapy during the forecast period. The market in the region is projected to expand at a high CAGR from 2021 to 2031. Increase in Incidence of Cancer and Strong Product Pipeline to Drive Global Market Increase in incidence of cancer and strong product pipeline are anticipated to boost the growth of the global CAR T-cell therapy market. According to the WHO, one in five people develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. According to the WHO, in 2020, around 544,352 new cases of non-Hodgkin lymphoma were recorded globally. Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83242 Strong product pipeline is a major factor driving the demand for CAR T-cell therapy products. For instance, Autolus Therapeutics plc has one innovative product, AUTO1, in phase I trial for treatment of adult acute lymphoblastic leukemia. AUTO1 contains obecabtagene autoleucel, which is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Axicabtagene Ciloleucel to Dominate CAR T-cell Therapy Market In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others. The axicabtagene ciloleucel segment dominated the global CAR T-cell therapy market in 2020 and the trend is expected to continue during the forecast period. Yescarta is a product, which contains axicabtagene ciloleucel. Increase in demand for Yescarta in the treatment of diffuse large B-cell lymphoma and follicular lymphoma is likely to boost the growth of the segment during the forecast period. In October 2017, Kite Pharma, Inc. received the U.S. FDA approval for Yescarta for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Tisagenlecleucel was the second largest segment in terms of market share in 2020. Increase in demand for Kymriah for treatment of acute lymphoblastic lymphoma and product approval in different countries are likely to drive the segment. Diffuse Large B-cell Lymphoma to be Highly Lucrative Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. The diffuse large B-cell lymphoma segment dominated the CAR T-cell therapy market due to increase in incidence of diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Increase in number of cases of non-Hodgkin lymphoma is likely to propel the segment during the forecast period. According to WHO, globally, around 544,352 new non-Hodgkin lymphoma cases were recorded in 2020. Hospitals to Emerge as Significant End-user In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers. The hospitals segment led the global CAR T-cell therapy market in terms of revenue in 2020 and the trend is projected to continue during the forecast period. The hospitalization for cancer treatment is anticipated to boost the growth of the hospitals segment. Moreover, increase in use of CAR T-Cell therapy in the treatment of cancers contributes to the segment's large market share. The segment is driven by surge in number of cancer patients who visit hospital for treatment of cancer. North America to Dominate CAR T-cell Therapy Market In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global CAR T-cell therapy market in 2020, followed by Europe. North America’s large market share can be ascribed to technologically advanced research and treatment platforms, increase in number of cancer patients, new product launches, and presence of major players. The CAR T-cell therapy market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2031. This can be ascribed to the presence of developing countries with commercial hubs, expansion of business organizations, rise in awareness about CAR T-cell therapy, improvement in healthcare infrastructure, and increase in investments by companies. Competition Landscape The global CAR T-cell therapy market is consolidated due to limited approved products. Key players operating in the global market include Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc. Request For Custom Research: https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=83242 Global CAR T-cell Therapy Market: Segmentation
About Us Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ Contact Rohit Bhisey Like it? Share it! More by this author |